Clinical Trials Logo

Inclusion Body Myositis clinical trials

View clinical trials related to Inclusion Body Myositis.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05721573 Active, not recruiting - Clinical trials for Inclusion Body Myositis

A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Start date: February 28, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis

NCT ID: NCT05046821 Active, not recruiting - Clinical trials for Inclusion Body Myositis

Sporadic Inclusion Body Myositis Natural History Study

INSPIRE-IBM
Start date: October 11, 2021
Phase:
Study type: Observational

This is a prospective natural history study on patients with clinically defined sIBM. Participants will be assessed every 6 months over two years (five visits total). We will include 150 participants, enrolled across 13 sites, with sporadic IBM, diagnosed according to established criteria.

NCT ID: NCT04975841 Active, not recruiting - Clinical trials for Inclusion Body Myositis

Inclusion Body Myositis Treatment With Celution Processed Adipose Derived Regenerative Cells

Start date: March 10, 2022
Phase: N/A
Study type: Interventional

This is an open-label, single arm study evaluating the safety for patients with Inclusion Body Myositis. A total of 9 subjects will be enrolled in the study. Subjects will be randomized to Part 1 or Part 2 of the study in blocks of 3 every 3 months. Stem cell injections will be given in the forearm and thigh on either the left or right side of the body, depending on which side meets criteria. The overall goal of this pilot study is to test the safety of adipose derived regenerative cells in patients with Inclusion Body Myositis. If determined safe, this trial could lead to larger Phase II trials. While this specific trial's primary endpoint is safety, it our ultimate hope that ADRC injections into the forearm and thigh of IBM patients will slow, stabilize, or even reverse the progression of muscle weakness in patients with IBM.

NCT ID: NCT04659031 Active, not recruiting - Clinical trials for Inclusion Body Myositis

A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)

Start date: May 25, 2021
Phase: Phase 1
Study type: Interventional

An open-label, ascending dose study for adult patients with Inclusion Body Myositis (IBM).